Biotech
Pivot Bio
Pivot Bio raises $430M Series D at $2B valuation
$430M
Total Raised
Series D
Latest Round
2011
Founded
250+
Employees
Berkeley, CA
1 min read
Quick Facts
Valuation
$2B
Latest Round Size
$430M
Latest Round Date
June 2021
Pivot Bio: Series D Funding Round
Pivot Bio has successfully raised $430M in Series D funding, reaching a valuation of $2B.
Company Overview
Nitrogen-producing microbes for agriculture
Funding Details
The Series D round was led by DCVC, with participation from Temasek.
Company Information
- Headquarters: Berkeley, CA
- Founded: 2011
- Employees: 250+
- Category: Biotech
Investment
Pivot Bio plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- DCVC: Verified investor in Series D
- Temasek: Verified investor in Series D
Key Investors
DCVC
Lead Investor
Verified investor in Series D
Temasek
Investor
Verified investor in Series D
About the Author
Editorial Team
Curated funding news from verified sources
Related Company Reports
Biotech
Orna Therapeutics
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Emma Rodriguez
Oct 23, 2025
0 min readβ’$251M Series B
Biotech
Forge Biologics
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Sarah Kim
Oct 23, 2025
0 min readβ’$120M Series C
Biotech
Vir Biotechnology
Vir Biotechnology Raises $250M
Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza
Sarah Kim
Oct 23, 2025
0 min readβ’$250M